Emina E Torlakovic, Nick Baniak, Penny J Barnes, Keith Chancey, Liam Chen, Carol Cheung, Sylvie Clairefond, Jean-Claude Cutz, Hala Faragalla, Denis H Gravel, Kelly Dakin Hache, Pratibha Iyengar, Michael Komel, Zuzana Kos, Magali Lacroix-Triki, Monna Marolt, Miralem Mrkonjic, Anna Marie Mulligan, Sharon Nofech-Mozes, Paul C Park, Anna Plotkin, Simon Raphael, Henrike Rees, H Rommel Seno, Duc-Vinh Thai, Megan L Troxell, Sonal Varma, Gang Wang, Tao Wang, Bret Wehrli, Gilbert Bigras
New therapies are being developed for breast cancer and in this process some "old" biomarkers are re-utilized and given a new purpose. It is not always recognized that, by changing a biomarker's intended use, a new biomarker assay is created. The Ki-67 biomarker is typically assessed by immunohistochemistry (IHC) to provide a proliferative index in breast cancer. Canadian laboratories assessed the analytical performance and diagnostic accuracy of their Ki-67 IHC laboratory developed tests (LDTs), of relevance for the LDTs' clinical utility...
May 8, 2024: Laboratory Investigation; a Journal of Technical Methods and Pathology